Tyrosine

Urinary tyrosine reflects the amino acid left in urine after your kidneys filter and reclaim it. A change can come from altered blood levels, kidney handling, diet, or treatment. The result alone doesn't identify which explanation is responsible.

Urine amino acid profiles have an established role in investigating inherited metabolic and transport disorders. Using tyrosine alone to screen healthy adults for early kidney or liver disease, or to guide longevity care, remains exploratory. Clinical laboratories publish method-specific reference intervals, but there is no validated urinary target for improving long-term health.

What the Number Represents

Tyrosine is an amino acid. Amino acids are the building blocks of proteins. You obtain it from food and from the breakdown of your own proteins, and your liver and kidneys can make it from phenylalanine. Cells also use it to produce dopamine, norepinephrine, adrenaline, skin pigment, and thyroid hormones.

Tyrosine breakdown occurs mainly in the liver. Your kidneys filter circulating tyrosine and normally reclaim most of it through their tubules. These are small channels that return useful substances to the blood. Urinary tyrosine therefore depends on both the amount reaching the kidneys and how the kidneys handle it.

This test measures tyrosine in urine using LC-MS. The laboratory separates compounds in the sample and detects tyrosine using its mass-related signal. Tyrosine breakdown products, N-acetyl-tyrosine, and dityrosine are separate molecules; findings about them aren't measurements of the tyrosine reported here.

Results are reported in mcg/g. The full unit label should identify what the gram refers to. Urine amino acid reports often use grams of creatinine, but that denominator needs confirmation for this result. A value adjusted for creatinine accounts partly for urine dilution; it does not measure total daily tyrosine loss. Creatinine is a waste product associated with muscle metabolism.

Inherited Problems With Tyrosine Metabolism

Hereditary tyrosinemias involve defects in tyrosine breakdown. Type I can cause serious liver and kidney disease and increases liver cancer risk. Types II and III involve different enzymes and have different clinical features. Urinary tyrosine may contribute to a broader biochemical pattern, but it cannot establish the type or exclude one of these disorders.

For type I, succinylacetone in blood or urine is the key biochemical marker. It is a separate compound that accumulates when this breakdown pathway is blocked. Tyrosine may still be unremarkable in an affected newborn. Evidence from newborn blood-spot screening supports succinylacetone-based screening; it does not validate an adult urine tyrosine screen.

Phenylketonuria affects the conversion of phenylalanine to tyrosine. Blood phenylalanine and its relationship to blood tyrosine help with evaluation. Alkaptonuria involves accumulation of the breakdown product homogentisic acid. Each disorder requires its own biochemical or genetic testing.

Kidney Handling

Kidney disease can change amino acid filtration, reabsorption, and production, so there isn't one urinary tyrosine pattern that identifies kidney damage. A high result can occur when amino acids are lost through the tubules, but a low result does not establish healthy kidneys.

In a human study of early kidney disease attributed to high blood pressure, urinary tyrosine was lower than in controls, with a similar difference in a separate validation group. The study used LC-MS and also found changes in genes and other compounds involved in kidney dopamine production. These were differences between groups, not proof that a falling result predicts kidney disease in an individual.

Human studies of advanced kidney failure also show reduced conversion of phenylalanine to tyrosine and lower circulating tyrosine. Those findings help explain the biology, but they do not establish what direction your urine result should take. Kidney filtration and urine protein measurements remain more directly useful for assessing kidney disease.

Liver Function

Liver disease can alter tyrosine breakdown. An older human study found higher fasting plasma tyrosine and slower clearance after a tyrosine dose in people with cirrhosis. The authors found these blood-based challenge tests unreliable for routine liver assessment. This does not establish ordinary urinary tyrosine as an early liver disease test.

A newer experiment gave mice a traceable form of tyrosine and measured labeled breakdown products in urine to investigate fatty liver inflammation. The same project examined human liver tissue, but the urine challenge was tested in mice. It is a different procedure from measuring naturally occurring urinary tyrosine.

Research in infants with citrin deficiency has also examined urinary organic acids produced during tyrosine breakdown. Those studies measured several related compounds, including 4-hydroxyphenyllactic acid, with a different analytical method. They do not show that urinary tyrosine alone diagnoses citrin deficiency.

What Blood Studies Show About Long-Term Risk

The following studies measured tyrosine in serum or plasma from blood samples. Their findings cannot be applied directly to a urine result, which also depends on kidney handling and the way urine concentration is reported.

These groups had different health problems, and the studies do not establish a single ideal tyrosine level. In the hospital study, low tyrosine did not consistently track the measured signs of poor nutrition. It cannot be assumed to mean that someone has eaten too little protein.

In another study of people undergoing evaluation for coronary disease, higher plasma tyrosine was associated with fewer subsequent cardiovascular events, while some compounds made from it by gut bacteria were associated with greater risk. Those compounds are separate analytes. The study does not support treating all tyrosine-related measurements as interchangeable.

A UK cohort analysis statistically attributed a small share of the association between worsening cardiovascular, kidney, and metabolic health and severe liver disease hospitalization to plasma tyrosine. The blood measurement method was NMR. This method identifies compounds through magnetic signals. The analysis cannot establish that tyrosine caused the liver outcomes or that urinary tyrosine predicts them.

Brain, Development, and Other Research Signals

A small LC-MS study of 75 children found higher urinary tyrosine concentrations in the autism group. Results were reported as concentration in urine, which uses a different reporting basis from this test's mcg/g value. The study did not establish a diagnostic threshold, and differences in group composition or urine dilution may affect interpretation.

A Parkinson's study analyzed 401 urine samples from 210 people and found differences across several metabolic pathways, including tyrosine metabolism. Another study compared preoperative urine from 66 children and found higher tyrosine in those who later developed agitation while waking from anesthesia. These exploratory findings do not establish this test as a way to diagnose autism, Parkinson's disease, or an individual risk of postoperative agitation.

When Results Can Be Misleading

• Collection conditions: food intake, collection time, and urine dilution can affect urine amino acid profiles. The size and direction of these effects vary, and a general finding about urine metabolites does not establish a specific change in tyrosine.
• Creatinine adjustment: if your result is divided by creatinine, differences in muscle mass, age, sex, and meat intake can change the ratio even when tyrosine excretion has not changed.
• Medication effects: nitisinone blocks tyrosine breakdown and raises tyrosine while treating a separate harmful part of the pathway. A rise during treatment does not by itself show worsening liver or kidney disease.
• Analytical interference: other substances in urine can suppress or increase LC-MS signals, and inadequate separation can allow interference. Appropriate calibration, internal standards, and method validation help control these problems; the method name alone does not guarantee that all interference has been removed.
• Sample handling and illness: storage conditions and the clinical situation matter when interpreting an amino acid profile. Results collected during acute illness may not represent your usual state.

What a Trend Can Mean

Repeated measurements can help distinguish a persistent finding from a single unusual sample. But there is no established size of change in this test that predicts disease progression or proves a health benefit. A stable result can coexist with illness, and a changing result needs an explanation beyond the direction of the number.